Drug profile · INN
pegloticase
KRYSTEXXA
pegloticase (KRYSTEXXA) is a uric acid oxidative enzyme. Route of administration: injection. Current US regulatory status: approved.
Drug details — pegloticase
- US status
- approved
- Class
- Musculo-skeletal system (M04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pegloticase (KRYSTEXXA) is a uric acid oxidative enzyme. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Uric acid oxidative enzyme
Primary target: Uric acid
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is pegloticase?
pegloticase (KRYSTEXXA) is a uric acid oxidative enzyme. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for pegloticase?
KRYSTEXXA is a marketed brand name for pegloticase. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegloticase?
pegloticase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.